mavoglurant Report issue

Small molecule Experimental
AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW
  • Now
Mavoglurant (developmental code name AFQ-056) is an experimental drug candidate for the treatment of fragile X syndrome and other conditions which has been discontinued. It exerts its effect as an antagonist of the metabotropic glutamate receptor 5 (mGluR5).   Wikipedia

Chemistry

  • SMILES: COC(=O)N1CC[C@@H]2[C@H]1CCC[C@@]2(O)C#Cc3cccc(C)c3
  • InChIKey: ZFPZEYHRWGMJCV-ZHALLVOQSA-N
  • Mol. Mass: 313.4
  • ALogP: 2.72
  • ChEMBL Molecule:
    mavoglurant  
More Chemistry

Pharmacology

Alternative names

afq056 | mavoglurant

Organizations (5)

Research & Development (5)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (20)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (20)


 

Alcohol Drinking (Phase 1)

Alcoholism (Early Phase 1)

Anti-Dyskinesia Agents (Phase 2)

Chorea (Phase 2)

Cigarette Smoking (Phase 1)

Cocaine-Related Disorders (Phase 2)

Dermatology (Phase 2)

Drugs, Investigational (Phase 2)

Dyskinesia, Drug-Induced (Phase 2)

Dyskinesias (Phase 2)

Fragile X Syndrome (Phase 2/Phase 3)

Gastroesophageal Reflux (Phase 1)

Huntington Disease (Phase 2)

Kidney Diseases (Phase 1)

Levodopa (Phase 2)

Liver Diseases (Phase 1)

Movement Disorders (Phase 2)

Obsessive Behavior (Phase 2)

Parkinson Disease (Phase 2)

Parkinsonian Disorders (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 25
  • # of Trial Organizations: 5

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue